Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment

January 24, 2024

https://www.globenewswire.com/news-release/2024/01/24/2815348/0/en/Altamira-Therapeutics-Files-Second-Provisional-Patent-Application-for-OligoPhore-Nanoparticles-Targeting-Different-KRAS-Mutations-in-Cancer-Treatment.html

HAMILTON, BERMUDA, Jan. 24, 2024 (GLOBE NEWSWIRE) —

HAMILTON, BERMUDA, Jan. 24, 2024 — Altamira Therapeutics Ltd. (Nasdaq:CYTO) (“Altamira” or the “Company”), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it has filed a second provisional patent application with the United States Patent and Trade Office (USPTO) to provide broad coverage of different KRAS mutations in human cancer treatment with nanoparticles comprising the Company’s OligoPhore™ platform and a single siRNA sequence, polyKRASmut. The nanoparticles are developed by Altamira as AM-401.

Read more at globenewswire.com

Related news for (CYTO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.